Holly L Geyer1, Bjorn Andreasson2, Heidi E Kosiorek3, Amylou C Dueck3, Robyn M Scherber4, Kari A Martin5, Kristina A Butler6, Claire N Harrison7, Deepti H Radia7, Francisco Cervantes8, Jean-Jacques Kiladjian9, Andreas Reiter10, Gunnar Birgegard11, Francesco Passamonti12, Zhenya Senyak13, Alessandro M Vannucchi14, Chiara Paoli15, Zhijian Xiao16, Jan Samuelsson17, Ruben A Mesa18. 1. Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, Arizona. 2. Internal Medicine, NU Hospital Organization, Uddevalla, Sweden. 3. Section of Biostatistics, Mayo Clinic, Scottsdale, Arizona. 4. Department of Hematology and Oncology, Oregon Health and Science University, Portland, Oregon. 5. Department of Psychiatry, Mayo Clinic, Scottsdale, Arizona. 6. Department of Gynecology, Mayo Clinic, Scottsdale, Arizona. 7. Department of Haematology, Guy's and St. Thomas NHS Foundation Trust, London, United Kingdom. 8. Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. 9. Clinical Investigation Center, Hospital Saint-Louis, Paris, France. 10. Medical Clinic, University of Mannheim, Mannheim, Germany. 11. Department of Hematology, University Hospital, Uppsala, Sweden. 12. Department of Hematology, IRCCS Foundation San Matteo Polyclinic, University of Pavia, Pavia, Italy. 13. MPN Forum, Asheville, North Carolina. 14. Division of Hematology, Circolo Hospital, Varese, Italy. 15. Department of Medicine, University of Florence, Florence, Italy. 16. MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. 17. Department of Internal Medicine, Stockholm South Hospital, Stockholm, Sweden. 18. Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona.
Abstract
BACKGROUND: Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODS: A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTS: Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. CONCLUSIONS: The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management. Cancer 2016;122:1888-96.
BACKGROUND:Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODS: A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTS: Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. CONCLUSIONS: The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management. Cancer 2016;122:1888-96.
Authors: Corien Eeltink; Alaa Embaby; Luca Incrocci; Johannes C F Ket; Sarah J Liptrott; Irma Verdonck-de Leeuw; Sonja Zweegman Journal: Support Care Cancer Date: 2022-01-21 Impact factor: 3.603